RE: Hi All13 Nov 2025 14:24
InnoMed Tech Ltd. (the "Company"), is pleased to announce that the Company has received conditional approval from the TSX Venture Exchange ("TSXV") for the listing of its common shares (the "Shares") on the TSXV, subject to completion of requirements of the TSXV, including receipt of all required documentation within a 90-day period from May 20, 2025.
The Company has filed its final Non-offering Long Form Prospectus (the "Prospectus") with the British Columbia Securities Commission.
The Prospectus contains important information relating to the Company, its business, and the risks associated with an investment in its securities. Investors are urged to read the Prospectus, which is available under the Company's profile on SEDAR+ at www.sedarplus.ca or on the Company's Website: www.InnomedTec.com.
Rob Rhodes, CEO, stated: "We are very pleased to reach this significant milestone of TSXV conditional listing approval on the TSX Venture Exchange. This achievement reflects our commitment to creating long-term value from our patented intellectual property for our shareholders and delivering our vision of developing and bringing medical innovations to market that improve clinical outcomes.
ABOUT INNOMED TECH.
The Company is in the business of medical devices and sciences within the global medical community.
The Company's first medical device development subsidiary, PureFlowCath, LLC, is delivering the PureFlowCath Catheter System for Continuous Irrigation ("CSCI"). CSCI addresses a significant market opportunity for reducing or eliminating urinary tract infections commonly associated with the use of urinary catheters. The Company was awarded various patents, including the European Patent, and is progressing the development of the PureFlowCath Catheter System to market.
ENQUIRIES
Billy Williams billy@wfgplanning.com
www.InnomedTec.com
Transaction Advisor CIC Capital Ltd.
Stuart J. Bromley Bromley@CICCapital.com